These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 21389097)

  • 1. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody.
    Fransen MF; Sluijter M; Morreau H; Arens R; Melief CJ
    Clin Cancer Res; 2011 Apr; 17(8):2270-80. PubMed ID: 21389097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of slow-release systems in CD40 agonistic antibody immunotherapy of cancer.
    Fransen MF; Cordfunke RA; Sluijter M; van Steenbergen MJ; Drijfhout JW; Ossendorp F; Hennink WE; Melief CJ
    Vaccine; 2014 Mar; 32(15):1654-60. PubMed ID: 24508038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity.
    van Mierlo GJ; den Boer AT; Medema JP; van der Voort EI; Fransen MF; Offringa R; Melief CJ; Toes RE
    Proc Natl Acad Sci U S A; 2002 Apr; 99(8):5561-6. PubMed ID: 11929985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor regression by anti-CD40 and interleukin-2: role of CD40 in hematopoietic cells and organ-specific effects.
    Welniak LA; Shorts L; Subleski J; Blazar BR; Wiltrout RH; Murphy WJ
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):534-9. PubMed ID: 15282531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer.
    Sandin LC; Orlova A; Gustafsson E; Ellmark P; Tolmachev V; Tötterman TH; Mangsbo SM
    Cancer Immunol Res; 2014 Jan; 2(1):80-90. PubMed ID: 24778163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors.
    Kudo-Saito C; Schlom J; Camphausen K; Coleman CN; Hodge JW
    Clin Cancer Res; 2005 Jun; 11(12):4533-44. PubMed ID: 15958639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combinatorial therapy for liver metastatic colon cancer: dendritic cell vaccine and low-dose agonistic anti-4-1BB antibody co-stimulatory signal.
    Lee H; Park HJ; Sohn HJ; Kim JM; Kim SJ
    J Surg Res; 2011 Jul; 169(1):e43-50. PubMed ID: 21571303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells.
    Kikuchi T; Miyazawa N; Moore MA; Crystal RG
    Cancer Res; 2000 Nov; 60(22):6391-5. PubMed ID: 11103803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effects.
    Fransen MF; van der Sluis TC; Ossendorp F; Arens R; Melief CJ
    Clin Cancer Res; 2013 Oct; 19(19):5381-9. PubMed ID: 23788581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eradication of established tumors in mice by a combination antibody-based therapy.
    Uno T; Takeda K; Kojima Y; Yoshizawa H; Akiba H; Mittler RS; Gejyo F; Okumura K; Yagita H; Smyth MJ
    Nat Med; 2006 Jun; 12(6):693-8. PubMed ID: 16680149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma.
    Xu DP; Sauter BV; Huang TG; Meseck M; Woo SL; Chen SH
    Gene Ther; 2005 Oct; 12(20):1526-33. PubMed ID: 15973445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclophosphamide inhibition of anti-CD40 monoclonal antibody-based therapy of B cell lymphoma is dependent on CD11b+ cells.
    Honeychurch J; Glennie MJ; Illidge TM
    Cancer Res; 2005 Aug; 65(16):7493-501. PubMed ID: 16103104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
    Hao S; Yuan J; Xiang J
    J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8+ T-cell density and activity, and enlarges draining lymph nodes.
    Søndergaard H; Galsgaard ED; Bartholomaeussen M; Straten PT; Odum N; Skak K
    J Immunother; 2010 Apr; 33(3):236-49. PubMed ID: 20445344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer immunotherapy using in vitro genetically modified targeted dendritic cells.
    Wei H; Wang H; Lu B; Li B; Hou S; Qian W; Fan K; Dai J; Zhao J; Guo Y
    Cancer Res; 2008 May; 68(10):3854-62. PubMed ID: 18483270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of agonistic anti-CD40 therapy in treatments for cancer.
    Khong A; Nelson DJ; Nowak AK; Lake RA; Robinson BW
    Int Rev Immunol; 2012 Aug; 31(4):246-66. PubMed ID: 22804570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy.
    Diehl L; den Boer AT; Schoenberger SP; van der Voort EI; Schumacher TN; Melief CJ; Offringa R; Toes RE
    Nat Med; 1999 Jul; 5(7):774-9. PubMed ID: 10395322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of tumor-specific acquired immunity against already established tumors by selective stimulation of innate DEC-205(+) dendritic cells.
    Moriya K; Wakabayashi A; Shimizu M; Tamura H; Dan K; Takahashi H
    Cancer Immunol Immunother; 2010 Jul; 59(7):1083-95. PubMed ID: 20221597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Agonistic anti-CD40 antibody therapy is effective against postoperative cancer recurrence and metastasis in a murine tumor model.
    Khong A; Brown MD; Vivian JB; Robinson BW; Currie AJ
    J Immunother; 2013 Sep; 36(7):365-72. PubMed ID: 23924788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymeric microparticles for sustained and local delivery of antiCD40 and antiCTLA-4 in immunotherapy of cancer.
    Rahimian S; Fransen MF; Kleinovink JW; Amidi M; Ossendorp F; Hennink WE
    Biomaterials; 2015 Aug; 61():33-40. PubMed ID: 25993015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.